CasNx, one of the selected startups, has developed a novel antivirus treatment for organs from organ donors. The company's gene-editing CRISPR kit eliminates viruses and installs universal donor markers while the organ is being preserved outside the body. This technology has the potential to increase the availability of organs for transplantation and reduce the risk of organ rejection. "Our goal is to make organ donation safer and more efficient," said a representative from CasNx. "We believe that our technology can help bridge the gap between the demand for organs and the supply."

Chipiron is another notable startup that is working on a light and inexpensive, open full-body MRI machine. The machine is being built using a superconducting quantum interference device (SQUID), a highly sensitive magnetometer that can measure extremely weak magnetic fields. This technology has the potential to make MRI cancer diagnostics more widely available, particularly in developing countries where access to MRI machines is limited. "We're excited about the potential of our technology to democratize access to MRI scans," said a representative from Chipiron.

Other notable biotech startups selected by TechCrunch include:

- Aethere, which is developing a non-invasive, wearable device that can detect early-stage cancer biomarkers in the body.
- BioLumina, which is working on a novel platform for developing personalized cancer treatments.
- Cerebro, which is developing a non-invasive brain-computer interface that can help people with paralysis communicate more effectively.
- EchoPlex, which is working on a novel platform for developing personalized treatments for neurological disorders.
- GeneSpark, which is developing a novel gene-editing technology for treating genetic diseases.
- NeuroSpark, which is working on a novel platform for developing personalized treatments for neurological disorders.
- OncoPlex, which is developing a novel platform for developing personalized cancer treatments.
- Synapse, which is working on a novel platform for developing personalized treatments for neurological disorders.

The selected startups have the potential to make a significant impact on the biotech and pharma industries. With their innovative approaches and cutting-edge technologies, they are poised to revolutionize the way we approach healthcare challenges. As the industry continues to evolve, it will be exciting to see how these startups develop and grow.

In the near future, these startups are expected to continue developing their technologies and preparing for clinical trials. CasNx plans to begin human trials for its antivirus treatment in the next year, while Chipiron is working on refining its MRI machine technology. The other selected startups are also expected to make significant progress in the coming years, with several planning to begin human trials in the next 12-18 months. As the biotech and pharma industries continue to evolve, it will be exciting to see how these startups contribute to the development of new treatments and technologies.